Work

A phase 2 study to assess olaparib by homologous recombination deficiency status in patients with platinum-sensitive, relapsed, ovarian, fallopian tube, or primary peritoneal cancer.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps5606

Authors: Karen Anne Cadoo, Carol Aghajanian, Cindy Fraser, Alvin Milner, Geert Kolvenbag

Institutions: Memorial Sloan Kettering Cancer Center, AstraZeneca (United Kingdom), Kurabo Industries Ltd. (Japan)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891966611

Cites:

Cited by: 3

Related to: 10